Page last updated: 2024-11-05

s-trioxane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

s-Trioxane, also known as 1,3,5-trioxane, is a cyclic organic compound with the formula (CH2O)3. It is a colorless, crystalline solid with a sweet odor. s-Trioxane is a stable compound that can be synthesized by the trimerization of formaldehyde. It is used as a disinfectant, fungicide, and preservative. s-Trioxane has also been studied for its potential use as a fuel and as a precursor to other organic compounds. The compound is of interest for its unique structural characteristics and its ability to undergo a variety of chemical reactions. For example, s-trioxane can be hydrolyzed to form formaldehyde, which is a valuable industrial chemical.'

s-trioxane: a 6-membered ring composed of 3 carbons and 3 oxygens [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1,3,5-trioxane : A saturated organic heteromonocyclic parent that is cyclohexane in which the carbon atoms at positions 1, 3 and 5 are replaced by oxygen atoms. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8081
CHEMBL ID1495792
CHEBI ID38043
MeSH IDM0057626

Synonyms (66)

Synonym
formaldehyde, trimer
flo-mor
metaformaldehyde
trioxane
formagene
trioxymethyleen
triossimetilene
s-trioxane
trioxymethylen
1,5-trioxane
triformol
1,5-trioxan
sym-trioxane
trioxymethylene
aldeform
marvosan
paraformal
1,5-trioxacyclohexane
nsc-26347
trioxan
s-trixane
wln: t6o co eotj
nsc26347
CHEBI:38043 ,
1,3,5-trioxacyclohexane
1,3,5-trioxan
1,3,5-trioxane
inchi=1/c3h6o3/c1-4-2-6-3-5-1/h1-3h
110-88-3
einecs 203-812-5
ai3-01363
nsc 26347
triossimetilene [italian]
ccris 4732
trioxymethyleen [dutch]
hsdb 3416
trioxymethylen [german]
1,3,5-trioxane, >=99%
T0505
NCGC00091660-02
AKOS005721175
tox21_200942
dtxcid501925
dtxsid4021925 ,
cas-110-88-3
NCGC00258496-01
BBL011407
BCP9000037
STL146511
46bnu65yny ,
unii-46bnu65yny
ec 203-812-5
FT-0606524
s-trioxane [mi]
1,3,5-trioxane [hsdb]
CHEMBL1495792
1.3,5-trioxane
J-503851
s-trioxan
F0001-0229
mfcd00006563
BCP23012
Q424104
E78845
1,3,5-trioxane 100 microg/ml in acetonitrile
1,3,5-trioxane anhydrous

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The studies on the accumulation of toxic effects of TOX and DOX have been carried out with the Kagan and StaƄkiewicz method."( [Experimental studies of the toxic effects of 1,3,5-trioxane and 1,3-dioxolane. II. Cumulation of toxic effect].
Czajkowska, T; Krysiak, B, 1987
)
0.27
" administration of trioxane produced no chromosomal damage resulting in erythrocyte micronucleus formation, even at highly toxic doses."( Genotoxic effects of dioxolane and trioxane in mice evaluated by the micronucleus test.
DziubaƂtowska, E; Kowalski, Z; Przybojewska, B, 1984
)
0.27

Compound-Compound Interactions

ExcerptReferenceRelevance
"8 mg/kg of monomeric trioxane 4b combined with 20 mg/kg of mefloquine hydrochloride, all of the malaria-infected mice lived until at least day 30 post infection."( Malaria-infected mice live until at least day 30 after a new monomeric trioxane combined with mefloquine are administered together in a single low oral dose.
Chang, W; Chen, X; Liu, JO; Posner, GH; Shapiro, TA; Woodard, LE, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
trioxane
saturated organic heteromonocyclic parent
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
interleukin 8Homo sapiens (human)Potency66.82420.047349.480674.9780AID651758
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.84890.001318.074339.8107AID926; AID938
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency35.80420.003041.611522,387.1992AID1159552; AID1159555
estrogen nuclear receptor alphaHomo sapiens (human)Potency3.58650.000229.305416,493.5996AID743069
gemininHomo sapiens (human)Potency13.33590.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency8.08750.005612.367736.1254AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (38.10)18.7374
1990's6 (28.57)18.2507
2000's4 (19.05)29.6817
2010's3 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.49 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (4.55%)4.05%
Observational0 (0.00%)0.25%
Other21 (95.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]